Zoetis Inc. $ZTS Shares Sold by Cypress Capital Group

Cypress Capital Group lowered its holdings in Zoetis Inc. (NYSE:ZTS) by 1.8% in the second quarter, Holdings Channel.com reports. The fund owned 14,101 shares of the company’s stock after selling 257 shares during the quarter. Cypress Capital Group’s holdings in Zoetis were worth $2,199,000 at the end of the most recent reporting period.

Other institutional investors also recently made changes to their positions in the company. Brighton Jones LLC boosted its holdings in Zoetis by 180.4% during the fourth quarter. Brighton Jones LLC now owns 4,629 shares of the company’s stock worth $754,000 after buying an additional 2,978 shares in the last quarter. Southland Equity Partners LLC acquired a new stake in shares of Zoetis during the 1st quarter valued at approximately $207,000. Opal Wealth Advisors LLC purchased a new stake in shares of Zoetis during the 1st quarter worth approximately $198,000. Dynamic Advisor Solutions LLC acquired a new stake in shares of Zoetis in the 1st quarter worth approximately $1,253,000. Finally, Ritholtz Wealth Management increased its stake in Zoetis by 7.1% in the 1st quarter. Ritholtz Wealth Management now owns 21,062 shares of the company’s stock valued at $3,468,000 after purchasing an additional 1,400 shares in the last quarter. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have commented on ZTS shares. Stifel Nicolaus downgraded Zoetis from a “buy” rating to a “hold” rating and decreased their target price for the stock from $165.00 to $160.00 in a research report on Wednesday, June 18th. Leerink Partners downgraded Zoetis from an “outperform” rating to a “market perform” rating and cut their price target for the stock from $180.00 to $155.00 in a research note on Thursday, July 17th. Weiss Ratings reissued a “hold (c-)” rating on shares of Zoetis in a research note on Wednesday, October 8th. Piper Sandler lifted their target price on shares of Zoetis from $210.00 to $215.00 and gave the stock an “overweight” rating in a research report on Monday, August 11th. Finally, Leerink Partnrs downgraded shares of Zoetis from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 17th. Four equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Zoetis has an average rating of “Hold” and a consensus target price of $196.71.

Zoetis Trading Down 1.6%

Shares of ZTS stock opened at $141.05 on Monday. The firm has a 50-day moving average price of $149.24 and a 200 day moving average price of $154.33. Zoetis Inc. has a twelve month low of $139.34 and a twelve month high of $196.55. The company has a market capitalization of $62.51 billion, a price-to-earnings ratio of 24.28, a PEG ratio of 2.26 and a beta of 0.90. The company has a current ratio of 1.76, a quick ratio of 1.04 and a debt-to-equity ratio of 1.05.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.62 by $0.14. The company had revenue of $2.46 billion for the quarter, compared to analysts’ expectations of $2.41 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The firm’s revenue for the quarter was up 4.2% compared to the same quarter last year. During the same period last year, the company earned $1.56 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Research analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 2nd. Shareholders of record on Friday, October 31st will be paid a $0.50 dividend. This represents a $2.00 annualized dividend and a yield of 1.4%. The ex-dividend date of this dividend is Friday, October 31st. Zoetis’s payout ratio is presently 34.42%.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.